( ractory group the following patients r...)Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO,Health

ractory group, the following patients responded: -- 1 patient with 4 prior regimens had a confirmed partial response after 2 cycles and continues in the trial for more than one year (cycle 23+; M-spike best decrease 96%); -- 1 patient with 3 prior regimens had a confirmed partial response after 2 cycles and continues in the trial after more than 46 weeks (cycle 15+; urinary M-protein not measurable); and -- 1 patient with 7 prior regimens had a confirmed partial response after 3 cycles and was in the trial for 23 weeks (completed 8 cycles; M-spike maximal decrease 89%) and was removed from study while still in partial response; 4 months later, the patient remains in partial response (total 39+ weeks).

Of the 9 patients treated thus far with the new tanespimycin injectable suspension, 5 patients are evaluable and 3 patients to date have demonstrated a response.

The combination of tanespimycin and bortezomib was well-tolerated. There was no significant increase in toxicity observed in the combination of tanespimycin and bortezomib when compared with historic single agent bortezomib experience. Common toxicities, which were mild-to-moderate as well as manageable and reversible, were primarily gastrointestinal events (diarrhea, nausea, vomiting), fatigue, elevated liver function tests, myalgia and peripheral edema. Common toxicities associated with bortezomib included thrombocytopenia (Grade 3-4 at 1.3 mg/m2) and neuropathy (Grade 1-2, at 1.3 mg/m2); importantly, the rate of peripheral neuropathy was relatively low. No cardiovascular toxicity and no Cremophor hypersensitivity were observed.

TIME Registration Program to Begin 3Q07

Kosan's TIME registration program is on track to be initiated in the third quarter of 2007. The TIME program includes two trials. TIME-2 is anticipated to begin in the third quarter of 2007, followed one to two quarters later by TIM
'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference